We are 4,5-Bis(2-methoxyethoxy)-2-nitrobenzonitrile CAS:236750-65-5 manufacturer and supplier in China, Pls send inquiry of to email@example.com of visit www.nbinno.com our official website should you have any interests
Chemical Name: 4,5-Bis(2-methoxyethoxy)-2-nitrobenzonitrile
Molecular Formula: C13H16N2O6
Physical and Chemical Properties:
Boiling point: 459.3ºC at 760 mmHg
Melting point: /
Flash point: 231.6±28.7 °C
Refractive index: 1.527
Appearance: White Powder
25kg cardboard drum or according to customer specified requirements
Storage:Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Application:Intermediates of Erlotinib hydrochloride CAS:183319-69-9
Related News: Retrogenix’s proprietary cell microarray technology provides a fast, accurate and effective solution for determining the primary target and secondary target (off-target) activities of antibodies, proteins, cell therapies, small molecules and viruses.(1R,2S)-1-Amino-N-(cyclopropylsulfonyl)-2-ethenylcyclopropanecarboxamide 4-methylbenzenesulfonate CAS:1028252-16-5 The policy-oriented emphasis on the medical and pharmaceutical industries and the direct support for the chemical raw material pharmaceutical industry have created a good political environment for the development of related enterprises and laid the foundation for the rapid development of the chemical raw material pharmaceutical industry. The good development prospects of the chemical raw material pharmaceutical industry will be passed directly to the upstream raw material industry, which will help stimulate the demand for the pharmaceutical intermediate market.4-methoxy-5-(3-morpholin-4-ylpropoxy)-2-nitrobenzonitrile CAS:675126-26-8 APIs are generally manufactured through a variety of processes that include.p-Anisidine Therefore, the R & D capabilities and registration capabilities of API companies have become the core factors of competition.The rigosertib Pre-approval Access Program is expected to launch in first half of 2020 and will allow Inceptua to supply intravenous rigosertib within designated countries, primarily and initially concentrated in selected countries in Europe, in response to physician requests for patients with higher-risk MDS who have exhausted all available treatment options, and are not eligible for or have no access to the INSPIRE study.